Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions
Authors:
- 9 March 2017
- journal article
- review article
- Published by SAGE Publications in Lupus
- Vol. 26 (10) , 1015-1022
Abstract
Intravenous immunoglobulin (IVIg) is increasingly used for the treatment of autoimmune and systemic inflammatory diseases. This compound is effective in a wide range of clinical conditions other than primary immunodeficiency, including autoimmune diseases, inflammatory disorders, infections, organ transplantation, and possibly supportive therapy for cancer. Systemic corticosteroids remain the gold standard treatment for many autoimmune diseases, but their long-term use is associated with complications in diverse organs and systems. Osteoporosis, osteonecrosis, cardiovascular disease, infections, and cancer have been associated with this treatment. Therefore, physicians are occasionally forced to withdraw the treatment with steroids. Biological agents may represent a good alternative, but in addition to being very expensive, these agents may have serious side effects. This review aimed to cover the major advances in the use of IVIg as a steroid-sparing agent in some relevant autoimmune diseases.Keywords
This publication has 47 references indexed in Scilit:
- Complications of Immunosuppressive Therapy in Solid Organ TransplantationRadiologic Clinics of North America, 2016
- The importance of glucocorticoid receptors in systemic lupus erythaematosus. A systematic reviewAutoimmunity Reviews, 2015
- Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studiesAutoimmunity Reviews, 2015
- Rituximab in Systemic Lupus Erythematosus and Lupus NephritisNephron Clinical Practice, 2014
- Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugsSeminars in Arthritis and Rheumatism, 2014
- Long-term complications of past glucocorticoid useAutoimmunity Reviews, 2013
- Anti-TNF therapy: Safety aspects of taking the riskAutoimmunity Reviews, 2011
- Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort studyThe Lancet, 2009
- Biologic therapies in rheumatology: lessons learned, future directionsNature Reviews Drug Discovery, 2007
- Autoantibody Level Modification in Adult Patients with Idiopathic Thrombocytopenic Purpura following Intravenous Immunoglobulin TreatmentNatural Immunity, 1998